SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?


To: GeoDude who wrote (395)2/13/2002 2:56:40 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 724
 
NEW BRUNSWICK SCIENTIFIC CO., INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)

Three Months Ended Year Ended
December 31, December 31,
2001 2000 2001 2000

Net sales $17,253 $14,545 $60,294 $49,864

Operating costs and
expenses:
Cost of sales 10,180 8,726 36,265 29,710
Selling, general and
administrative
expenses 4,309 3,908 16,205 15,607
Research, development
and engineering
expenses 702 792 2,751 3,423
DGI research expenses -- 864 1,312 3,480
Non-recurring
severance costs -- -- 260 --

Total operating costs
and expenses 15,191 14,290 56,793 52,220

Income (loss) from
operations 2,062 255 3,501 (2,356)

Other income (expense):
Interest income 11 20 56 56
Interest expense (124) (170) (561) (638)
Other, net (37) (16) (113) (87)
Write-off of investment -- -- -- (950)
(150) (166) (618) (1,619)
Income (loss) before
income tax expense
(benefit)
and equity in
operations of DGI 1,912 89 2,883 (3,975)

Income tax expense
(benefit) 42 57 145 (48)
Income (loss) before
equity in operations
of DGI 1,870 32 2,738 (3,927)
Equity in operations
of DGI (34) -- (527) --
Net income (loss) $ 1,836 $32 $2,211 $ (3,927)

Basic income (loss)
per share $.27 $-- $.33 $(.59)
Diluted income (loss)
per share $.27 $-- $.33 $(.59)
Basic weighted average
number of
shares outstanding 6,749 6,703 6,738 6,640
Diluted weighted average
number of shares
outstanding 6,826 6,831 6,772 6,640

SOURCE: New Brunswick Scientific Co., Inc.



To: GeoDude who wrote (395)2/13/2002 3:45:43 PM
From: quidditch  Read Replies (1) | Respond to of 724
 
Not badly written--and even the substance was encouraging <gg>. However, the juxtaposition of the following two statements leads me to believe that the company is mis-communicating an aspect of the DGI investment:

Most significantly, the carrying value of our equity investment in 47-percent-owned DGI BioTechnologies, Inc., was reduced to zero during the fourth quarter of 2001 and the Company no longer has any future financial obligations related to DGI....Moreover, as a result of our retained ownership position, our shareholders maintain a substantial interest in DGI's attractive upside potential going forward,'' he said.

What charge or other non-recurring event caused carrying value to be reduced to zero? To couple the words "most significantly" (an implied positive) with "carrying value...reduced to zero" is either a misstatement or an error in emphasis. Carrying value does not necessarily have anything to do with "future financial obligations". Carrying value DOES relate to the value of an investment/asset on the company's balance sheet. Writing down an investment to zero may be a consequence of zero market value of an investment, indefinite future losses to be incurred by an investee (with negative stockholders' equity), market value less than cost and de minimis, a fully depreciated asset (not usually used in the context of an equity investment). Companies maintain carrying values of investees without having future obligations tied to the investment.
What am I missing by way of background that makes sense of this?

quid